Vistagen Therapeutics, Inc. (VTGN) News
Follow Vistagen Therapeutics, Inc. (VTGN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 26 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Weekly Recap: PALISADE-2 met SUDS endpoint and itruvone/refisolone Phase 2a
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) said PALISADE-2 met its SUDS primary endpoint (p=0.015) and plans a U.S. Phase 3 LSAS program of ~350 participants, while repeat dosing improved anticipatory anxiety in public sp
NEWS | Sep 28, 2026, 11:06 AM UTC
L
Vistagen Therapeutics unveils new corporate presentation highlighting Phase 3 fasedienol plans and clinical data
Vistagen Therapeutics began using a new corporate presentation summarizing clinical progress and a proposed Phase 3 LSAS trial for fasedienol.Key Highlights:Original SEC Filing: Vistagen Therapeutics, Inc. [ VTGN ] - 8-K
REGULATION | Sep 25, 2026, 01:15 PM UTC
L
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones fo
MNA | Sep 24, 2026, 04:32 PM UTC
L
Vistagen Reports Positive Exploratory Efficacy Signals for Fasedienol in Very Severe Social Anxiety
Vistagen reported positive exploratory efficacy signals for fasedienol nasal spray in participants with very severe social anxiety disorder.Key Highlights:Original SEC Filing: Vistagen Therapeutics, Inc. [ VTGN ] - 8-K -
REGULATION | Sep 24, 2026, 11:44 AM UTC
L
Vistagen (VTGN) Reports Positive Signals for Fasedienol in Very Severe SAD
Vistagen reported exploratory analyses showing statistically significant SUDS improvements with fasedienol vs placebo in very severe social anxiety disorder subgroups, including in a repeat-dose Phase 2a study and a post
NEWS | Sep 24, 2026, 11:02 AM UTC
H
Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
Exploratory research results presented at Psych Congress 2026 in New OrleansFull poster presentation can be found on “Publications” section of Company’s websiteSOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE)
GEOPOLITICS | Sep 24, 2026, 11:01 AM UTC
L
VTGN - Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
VTGN - Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
NEWS | Sep 24, 2026, 11:00 AM UTC
L
Vistagen reports positive fasedienol open-label extension data
Vistagen said preliminary open-label extension data showed fasedienol was well-tolerated and associated with clinically relevant improvement in social anxiety over four months.
EQUITY | Sep 22, 2026, 08:26 PM UTC
M
Vistagen reports preliminary positive OLE data for fasedienol in SAD
Preliminary PALISADE-4 open-label extension data for fasedienol nasal spray suggest it was well-tolerated up to 12 months, with exploratory improvements on LSAS and SPIN over four months. Company plans to meet the FDA to
EQUITY | Sep 22, 2026, 12:34 PM UTC
M
Vistagen reports preliminary positive open-label extension data for fasedienol
Vistagen said fasedienol nasal spray was well-tolerated in social anxiety disorder patients, with no new drug-related safety findings after as-needed use for up to 12 months. The company reported clinically relevant impr
EQUITY | Sep 22, 2026, 12:33 PM UTC
L
VTGN - Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
VTGN - Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
NEWS | Sep 22, 2026, 12:30 PM UTC
L
VTGN directors elected, say on pay approved, auditor reappointed
The annual meeting passed all proposals, including election of four directors, approval of executive compensation and reappointment of KPMG as auditor for FY 2027.
EQUITY | Sep 10, 2026, 04:54 PM UTC
H
VTGN - Vistagen to Present at Psych Congress 2026
VTGN - Vistagen to Present at Psych Congress 2026
GEOPOLITICS | Sep 10, 2026, 12:32 PM UTC
L
Vistagen (VTGN) reports FY2027 first-quarter financial results
Vistagen (VTGN) reports its fiscal year 2027 first-quarter financial results alongside a corporate update, with no additional figures included in the provided material.
EARNINGS | Aug 14, 2026, 12:32 PM UTC
L
VTGN - Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder - Click For Rel
VTGN - Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
EQUITY | Aug 06, 2026, 12:30 PM UTC
H
Premarket Gainers: RAIN +101.87%
Top premarket gainers
EQUITY | Aug 04, 2026, 09:40 AM UTC
H
SRX Global Acquires Stake in Vistagen
SRX Global buys stake in Vistagen Therapeutics
MNA | Aug 04, 2026, 09:00 AM UTC
L
VTGN Appoints Douglas Williamson to Board
VTGN appoints new board member
EQUITY | Jul 31, 2026, 12:30 PM UTC
L
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss
Vistagen Inc. (NASDAQ: VTGN ) on Monday reported that its Phase 3 PALISADE-4 trial of intranasal fasedienol for the acute treatment of social anxiety disorder did not meet its primary endpoint in the overall study popula
REGULATION | Jun 30, 2026, 05:35 PM UTC
L
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Creative Medical Tech (NASDAQ: CELZ ) stock moved upwards by 242.5% to $2.77 during Tuesday's regular session. The market value of their outstanding shares is at $2.9 million. Cuprina Holdings (Cayman) (NASDAQ: C
EQUITY | Jun 30, 2026, 05:05 PM UTC
L
Nasdaq Gains Over 300 Points; Chicago PMI Falls In June
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 300 points on Tuesday. The Dow traded up 0.28% to 52,327.93 while the NASDAQ rose 1.31% to 26,157.23. The S&P 500 also rose, gainin
MACRO | Jun 30, 2026, 04:08 PM UTC
L
US Stocks Mixed; Home Prices Increase 1.1% In April
U.S. stocks traded mixed this morning, with the Dow Jones index falling around 0.2% on Tuesday. Following the market opening Tuesday, the Dow traded down 0.18% to 52,091.03 while the NASDAQ rose 0.36% to 25,912.25. The S
RATES | Jun 30, 2026, 01:47 PM UTC
L
Vistagen Therapeutics shares are trading lower after the company announced topline results from the PALISADE-4 Phase 3 trial. Fasedienol did
Vistagen Therapeutics shares are trading lower after the company announced topline results from the PALISADE-4 Phase 3 trial. Fasedienol did not achieve its primary endpoint and there was no treatment difference between
EQUITY | Jun 30, 2026, 01:28 PM UTC
L
Trading Halt: Halt status updated at 8:15:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halt status updated at 8:15:00 AM ET: Quotation Resumption: News and Resumption Times
EQUITY | Jun 30, 2026, 12:15 PM UTC
H
Vistagen Announces Topline Results From Its PALISADE-4 Phase 3 Trial Of Intranasal Fasedienol To Treat Social Anxiety Disorder; Fasedienol D
PALISADE-4 was a U.S. multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to evaluate the efficacy, safety, and tolerability of a single dose of fasedienol in reducing anxiety sympt
EARNINGS | Jun 30, 2026, 12:09 PM UTC
L
Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending
Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending
EQUITY | Jun 30, 2026, 11:55 AM UTC